Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus esketamine for non-intubated hysteroscopic surgery
ChiCTR2400088162Phase 4Not yet recruiting
- Sponsor
- Zhuji People's Hospital of Zhejiang Province
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, esketamine and propofol in hysteroscopic surgery (3 arms), sponsored by Zhuji People's Hospital of Zhejiang Province. Primary endpoints: ED90 of remimazolam combined with esketamine and Time from immediate induction to loss of consciousness. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
remimazolamesketaminepropofol
03
Conditions
hysteroscopic surgery
Beyond the preview
Go deeper on ChiCTR2400088162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088162.